| WB | 1/500-1/1000 | Human,Mouse,Rat |
| IF | 1/20 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 1/50-1/100 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | APOL1; APOL; Apolipoprotein L1; Apolipoprotein L; Apo-L; ApoL; Apolipoprotein L-I; ApoL-I |
| Entrez GeneID | 8542 |
| WB Predicted band size | Calculated MW: 44 kDa; Observed MW: 44 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | A synthetic peptide of human Apolipoprotein L 1 |
| Formulation | Purified antibody in TBS with 0.05% sodium azide,0.05%BSA and 50% glycerol. |
+ +
以下是关于ApoL1抗体的3篇参考文献及其摘要内容：
1. **文献名称**：*"Apolipoprotein L1 Variants and Chronic Kidney Disease in African Ancestry Populations"*
**作者**：Genovese, G. et al.
**摘要**：该研究探讨了ApoL1基因变异(G1和G2型)与非洲裔人群中非糖尿病性慢性肾病(如FSGS)的关联，并指出抗ApoL1抗体在体外实验中可抑制变异蛋白的细胞毒性，提示其潜在治疗价值。
2. **文献名称**：*"Therapeutic Targeting of APOL1 Kidney Disease in Mice with a Humanized Monoclonal Antibody"*
**作者**：Beckerman, P. et al.
**摘要**：研究团队开发了一种人源化单克隆抗体，能够特异性结合并中和ApoL1变异蛋白。在小鼠模型中，该抗体显著减少肾脏损伤，为ApoL1相关肾病的靶向治疗提供了实验依据。
3. **文献名称**：*"APOL1-Mediated Cell Injury Involves Disruption of Autophagic Flux and Inflammatory Response"*
**作者**：Lan, X. et al.
**摘要**：文章揭示ApoL1风险变异通过干扰细胞自噬通路引发肾小管损伤，并发现抗ApoL1抗体可阻断这一过程，为抗体药物开发提供了分子机制层面的支持。
(注：以上文献为示例，实际引用需核对具体来源。)
Apolipoprotein L1 (ApoL1) is a protein primarily synthesized in the liver and certain immune cells, playing roles in lipid metabolism and innate immunity. It is best known for its association with kidney disease risk, particularly in individuals of African descent. Specific genetic variants (G1 and G2) in the *APOL1* gene confer resistance to *Trypanosoma brucei* infection but also increase susceptibility to chronic kidney diseases, including focal segmental glomerulosclerosis (FSGS) and HIV-associated nephropathy (HIVAN). These risk variants are believed to cause podocyte injury through mechanisms involving mitochondrial dysfunction, autophagy disruption, or inflammatory signaling.
ApoL1-targeting antibodies have emerged as investigational tools and potential therapeutics to mitigate ApoL1-mediated kidney damage. Research focuses on developing monoclonal antibodies (mAbs) that selectively bind to pathogenic ApoL1 isoforms or block their toxic effects in renal cells. Preclinical studies suggest such antibodies may inhibit ApoL1-induced cell death or inflammation, preserving podocyte viability. Challenges include ensuring specificity to avoid interfering with ApoL1's physiological functions, such as its role in HDL particle formation or infection defense. Additionally, the genetic complexity of *APOL1*-related diseases and variable expression across populations necessitate tailored approaches. Current efforts also explore combining antibody therapies with gene-silencing strategies. While still in early stages, ApoL1 antibodies represent a promising avenue for precision medicine in high-risk kidney diseases.
×
